Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 1Hypertension 1Hot Flashes 1Diabetes Mellitus 1Depressive Disorder, Major 1Depression 1Cardiovascular Diseases 1Breast Neoplasms 1

Interventions

Surveys and Questionnaires 114Exercise 103Blood Specimen Collection 99Radiotherapy 67Gemcitabine 64Bevacizumab 57Standard of Care 56Cisplatin 55Cyclophosphamide 51Capecitabine 50Carboplatin 49Docetaxel 47pembrolizumab 46Dexamethasone 46Paclitaxel 45Interviews as Topic 43Oxaliplatin 40Magnetic Resonance Spectroscopy 39Fluorouracil 37Methods 36Irinotecan 36Therapeutics 33Drug Therapy 33Radiosurgery 31Nivolumab 30Erlotinib Hydrochloride 27Educational Status 26Everolimus 24Leucovorin 23Control Groups 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neoplasms × Desvenlafaxine Succinate × Clear all
NCT01803711 2017-12-27

Omega 3 FA Supplements as Augmentation in the Treatment of Depression

UConn Health

Phase 2/3 Terminated
6 enrolled 4 charts

Cardiovascular Diseases, Depression, Depressive Disorder, Major, Diabetes Mellitus, Hypertension, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡